These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25482382)

  • 41. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
    Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
    Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 44. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
    Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
    Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
    Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
    Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.
    Dargaud Y; Desmurs-Clavel H; Marin S; Bordet JC; Poplavsky JL; Negrier C
    J Thromb Haemost; 2008 Jun; 6(6):962-8. PubMed ID: 18373620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
    Allen GA; Hoffman M; Roberts HR; Monroe DM
    Br J Haematol; 2006 Aug; 134(3):314-9. PubMed ID: 16787497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents.
    Bar J; David A; Khader T; Mulcare M; Tedeschi C
    Prehosp Disaster Med; 2017 Oct; 32(5):580-587. PubMed ID: 28625215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA.
    Gallistl S; Cvirn G; Leschnik B; Muntean W
    Blood Coagul Fibrinolysis; 2002 Oct; 13(7):653-5. PubMed ID: 12439153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
    Brophy DF; Martin EJ; Barrett JC; Nolte ME; Kuhn JG; Hedner U; Ezban M
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ROTEM monitoring of activated and non-activated prothrombin complex concentrate correction of dilutional coagulopathy.
    Elvstam O; Berntorp E; Schött U
    Scand J Clin Lab Invest; 2016; 76(3):202-7. PubMed ID: 26898225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
    Klintman J; Astermark J; Berntorp E
    Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness.
    Yada K; Nogami K; Ogiwara K; Shima M
    J Thromb Haemost; 2013 May; 11(5):902-10. PubMed ID: 23517528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
    Tran HT; Sørensen B; Rea CJ; Bjørnsen S; Ueland T; Pripp AH; Tjønnfjord GE; Holme PA
    Haemophilia; 2014 May; 20(3):369-75. PubMed ID: 24251535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
    Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.
    Takeyama M; Kasuda S; Sakurai Y; Shima M; Takeda T; Omura S; Naka H; Yoshioka A
    Int J Hematol; 2007 Jun; 85(5):397-402. PubMed ID: 17562614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on the mechanism of action and future of activated prothrombin complex concentrates.
    Turecek PL; Váradi K; Schwarz HP
    Curr Hematol Rep; 2004 Sep; 3(5):331-7. PubMed ID: 15341699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
    Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.